LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

31.26

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.26

Massimo

31.35

Metriche Chiave
By Trading Economics
Entrata	11M 64M
Vendite	-3.2M 149M
P/E Media del settore	18.052 49.701
EPS	0.79
Margine di Profitto	42.663
Dipendenti	182
EBITDA	2M 83M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+5.82% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	281M 3.8B
Apertura precedente	31.26
Chiusura precedente	31.26

Notizie sul Sentiment di mercato

By Acuity

50%

148 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2026, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mag 2026, 16:49 UTC

Utili

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mag 2026, 16:26 UTC

I principali Market Mover

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mag 2026, 23:51 UTC

Discorsi di Mercato

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mag 2026, 22:33 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mag 2026, 21:53 UTC

Utili

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mag 2026, 21:02 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mag 2026, 20:55 UTC

Utili

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mag 2026, 20:30 UTC

Azioni calde

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Adj EPS 3c >BULL

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Rev $159.9M >BULL

21 mag 2026, 20:18 UTC

Discorsi di Mercato

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mag 2026, 20:18 UTC

Utili

Webull 1Q Loss/Shr 4c

21 mag 2026, 19:43 UTC

Discorsi di Mercato

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mag 2026, 18:58 UTC

Utili

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mag 2026, 18:15 UTC

Discorsi di Mercato

Gold Higher For Second Consecutive Day -- Market Talk

21 mag 2026, 17:40 UTC

Discorsi di Mercato

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mag 2026, 17:04 UTC

Discorsi di Mercato

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mag 2026, 17:01 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Stellantis Targets Distant but Constructive -- Market Talk

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

5.82% in crescita

Previsioni per 12 mesi

Media 33.1 USD 5.82%

Alto 35 USD

Basso 31.5 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

148 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.